ArticleClinical oral investigations2026
Evaluating dental developmental abnormalities in osteogenesis imperfecta: associations with timing and cumulative exposure to intravenous pamidronate- a pilot study.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesBisphosphonates are widely used in pediatric Osteogenesis Imperfecta (OI), but their potential impact on odontogenesis is not well characterized. We examined whether intravenous pamidronate exposure is associated with specific developmental dental abnormalities in OI, with particular attention to treatment timing, duration, cumulative exposure, and gender. MATERIALS AND
methodsFifty-eight individuals with OI (38 treated and 20 untreated) underwent standardized clinical examination and panoramic radiography. Outcomes included enamel hypoplasia, dentinogenesis imperfecta (DI), dens evaginatus (DE), microdontia, hypodontia, taurodontism, bulbous crowns, pulpal obliteration, short roots, root dilaceration, and tooth fractures. Treated individuals were further stratified by whether treatment began before or after age two years. Associations with treatment duration and cycle count were also evaluated.
resultsEnamel hypoplasia occurred only in treated participants (p = 0.005). Initiation of therapy before age two years was associated with a higher prevalence of enamel hypoplasia (p = 0.036). Enamel hypoplasia showed a significant association with treatment in females (p = 0.034). Root dilaceration was the only abnormality associated with cycle count (p = 0.008). Longer treatment duration was associated with DE (p = 0.021), microdontia (p = 0.026), and pulpal obliteration (p = 0.002).
conclusionsIn this exploratory pilot cohort, enamel hypoplasia showed the clearest association with pamidronate exposure, particularly when treatment began before age two years. Root dilaceration demonstrated a cumulative-exposure pattern. Other abnormalities appeared more strongly related to underlying disease severity than treatment variables. CLINICAL RELEVANCE: These findings underscore the importance of structured dental surveillance in children receiving pamidronates during early developmental windows.
Indexed as
Identifiers
42814194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.